People - Management

MicroPhage Management is comprised of a number of passionate and determined people who are driving the success of our technology and applications.

Management:

R. Gary Mesch Chief Executive Officer MicroPhage, Inc.

Mr. R. Gary Mesch is the new Chief Executive Officer of MicroPhage as of October 2007. Mr. Mesch has also served as the MicroPhage Chairman since June 2007. Mr. Mesch comes to MicroPhage as the current managing director of Alpine Angels, a Vail Valley-based angel investment group that organizes financing for and advises start-up technology companies. Mr Mesch is also an active director of several start-up companies funded through Alpine Angels members. Mr. Mesch has been the founder and Managing Director of several successful data and telecom companies operating in the U.S. and Europe and has been instrumental in launching several other start-up enterprises. Mr. Mesch founded VersaTel telecom in 1995 in Amsterdam and served as CEO and then Chairman until 2002. VersaTel grew to become the second facilities based telecom operator throughout The Netherlands, Belgium, and Germany. In 2005 Versatel was purchased by Tele2 of Sweden and Apax Partners for $1.5 billion. Previous to VersaTel, Mr. Mesch as Managing Director of Open Skies, Inc., a telecom consulting company based in Amsterdam, advised European telecom operators on launching innovative services. From 1984 to 1990 he was co-founder of Nova-Net communications, Inc. a Denver-based nationwide data network provider that was sold to ICG, a Denver-based CLEC telecom company. Mr Mesch holds a B.S. in Electrical Engineering from the University of Colorado and an MBA from the University of Denver.

John H. Wheeler Founder, Chief Marketing Officer MicroPhage, Inc.

Mr. Wheeler brings 30 years of business experience in the biomedical and diagnostics fields to the Company. Prior to founding MicroPhage Incorporated™ , Mr. Wheeler founded Xtrana, Inc.(NASDAQ:XTRN) as its President and CEO, a molecular diagnostics company specializing in nucleic acid extraction and detection. Previous to Xtrana, he served as Vice President of Sales, Marketing and Business Development at Xenometrix, Inc. a molecular toxicology company, from 1993 to 1997. From 1992 to 1993, Mr. Wheeler was Director of Sales and Marketing for Research Biochemicals, Ltd. and from 1987 to 1992, Mr. Wheeler was employed by Charles River Laboratories where he held positions including Director of Operations and Vice President of Sales and Marketing. Prior to 1987, he held positions in sales, marketing and strategic business planning both in the United States and Europe with Becton Dickinson Company. Mr. Wheeler received his M.B.A. from Pace University, New York in 1986 and his B.A. in biology from the University of Bridgeport in 1970. Mr. Wheeler currently serves as the Chair of the Colorado BioScience Association (CBSA), representing over 100 Colorado companies.

J. Drew Smith, Ph.D. Research and Development Director MicroPhage, Inc.

Dr. Smith comes to MicroPhage with experience leading diagnostic assays while at SomaLogic, Inc., a Boulder, CO based medical diagnostics firm. While at SomaLogic, Dr. Smith served as Director of aptamer development and senior research fellow where he worked on optimizing and automatizing the PhotoSELEX process, development of methods for detection of serum proteins by aptamer microarrays, and development of multiplexed aptamer microarray assays for detection of serum protein disease signatures. Dr. Smith is also a founding scientist at NeXagen and a principal scientist at Nexstar, both aptamer-based biotechnology companies based in Boulder, CO. Just prior to joining MicroPhage, Dr. Smith was at Aptamer NanoTechnologies, LLC, a company which he founded, working on developing proprietary DNA photoswitch technology for use in light-directed drug delivery. Dr. Smith has 17 patents to his credit in aptamer-based diagnostics and related areas. He earned his Ph.D. in 1988 on the genetic analysis of transfer RNA structure and translational kinetics at the University of Colorado, Boulder. He earned his B.A. in Biology at University of California, Santa Cruz in 1981.

Scott Conlin Marketing Director MicroPhage, Inc.

Mr. Conlin is a founding employee of MicroPhage, Inc., who started in June 2003 when the company was first located at the Colorado School of Mines. Mr. Conlin is responsible for the areas of Marketing, Clinical Development, Regulatory Affairs, Reimbursement Planning, and Information Technology for MicroPhage, making him more than the typical Marketing Director. Mr. Conlin comes to MicroPhage from the Boston, Massachusetts area where he served as Director of Marketing and Research for Quincy College, a public city chartered college. While at the College, Mr. Conlin taught as an adjunct instructor for courses in Marketing, Computer Science, and Design. His previous positions include Branch Manager and Marketing Coordinator at Hertz Local Edition as well as manager of People's Market, a natural foods cooperative specialty market. Mr. Conlin's undergraduate studies are in biochemistry and human nutrition while at the University of Massachusetts, Amherst. Mr. Conlin currently serves on the Colorado Biosciences Association (CBSA) Programs Committee and the Advanced Medical Technology Association (AdvaMed) Emerging Growth Company Council.

Michael Fiechtner, Ph.D. Director, Product Development MicroPhage, Inc.

Dr. Fiechtner has more than 25 years of research and product development experience in the diagnostics and life sciences industries. Immediately prior to joining MicroPhage, he was Principal Scientist at BD Rapid Diagnostics, where he helped establish a new R&D facility in San Diego. Previously he served as Director of Product Development for proteomic applications at Genicon Sciences, and for DNA probe assays at Nanogen, Inc. As Principal Scientist at Biosite, Inc., Dr. Fiechtner was responsible for the development of key components of the Triage Cardiac system. He also served as an Adjunct Lecturer in the Chemistry Department at the University of San Diego. From 1981 to 1993, Dr. Fiechtner held various research and development positions in the Diagnostics Division of Abbott Laboratories, where he developed an automated assay for glycated hemoglobin, widely used in diabetes monitoring. He earned his Ph.D. in chemistry from the University of Illinois at Chicago, and completed a postdoctoral fellowship at the University of Rochester. Dr. Fiechtner has been awarded 6 U.S. patents and several foreign patents.